The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial.

  title={The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial.},
  author={John M. Nolan and Ekaterina Loskutova and Alan N. Howard and R{\'i}ona Mulcahy and R Moran and Jim Stack and Maggie Bolger and Robert F. Coen and Jessica L. Dennison and Kwadwo Owusu Akuffo and Niamh Owens and Rebecca Power and D I Thurnham and Stephen Beatty},
  journal={Journal of Alzheimer's disease : JAD},
  volume={44 4},
BACKGROUND Patients with Alzheimer's disease (AD) exhibit significantly less macular pigment (MP) and poorer vision when compared to control subjects. OBJECTIVE To investigate supplementation with the macular carotenoids on MP, vision, and cognitive function in patients with AD versus controls. METHODS A randomized, double-blind clinical trial with placebo and active arms. 31 AD patients and 31 age-similar control subjects were supplemented for six months with either Macushield (10 mg meso… 

Figures and Tables from this paper

Cognitive Function and Its Relationship with Macular Pigment Optical Density and Serum Concentrations of its Constituent Carotenoids

Macular pigment offers potential as a non-invasive clinical biomarker of cognitive health, and appears more successful in this role than serum concentrations of L or Z.

Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease.

Following 12 months of supplementation, the active group compared to the placebo group, demonstrated statistically significant improvements in skinCarotenoid measurements, blood carotenoids, ω-3FAs, and vitamin E concentrations, and this combined micronutrient dietary supplement should be considered in the overall management of AD.

Macular carotenoid supplementation and visual function in early age-related macular degeneration

This thesis provides prevalence estimates of AMD in the ROI for the first time, and adds to the evidence with respect to the impact of macular carotenoid supplementation on visual function among patients with this condition.

Enrichment of Macular Pigment Enhances Contrast Sensitivity in Subjects Free of Retinal Disease: Central Retinal Enrichment Supplementation Trials - Report 1.

Results indicate that dietary fortification with the macular carotenoids can have meaningful effects on visual function.

Dietary Carotenoids Lutein and Zeaxanthin Change Brain Activation in Older Adult Participants: A Randomized, Double-Masked, Placebo-Controlled Trial.

Past research suggests that L+Z can improve visual memory, visual processing speeds, etc, and one possible mechanism for that improvement may be improving signal-to-noise ratio throughout the vision system.

Environmental and Nutritional Determinants of Macular Pigment in a Mexican Population

New data from a Mexican sample provide evidence of the multifactorial interactions and environmental determinants of MP such as sunlight exposure and dietary patterns and will be essential for future studies in Mexico for eye health, visual function, and ocular pathology.

The Associations of Plasma/Serum Carotenoids with Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Of six major members of carotenoids, only lutein and zeaxanthin concentrations in plasma/serum were inversely related to the risk of AD.

Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients

Dietary Lutein and Cognitive Function in Adults: A Meta-Analysis of Randomized Controlled Trials

Change-from-baseline analysis revealed that lutein consumption could have a role in maintaining cognitive performance in memory and executive function, and the evidence across multiple studies suggests that lutingin may nonetheless prevent cognitive decline, especially executive function.

The Effect of Lutein/Zeaxanthin Intake on Human Macular Pigment Optical Density: A Systematic Review and Meta-Analysis

Future research is needed to determine the minimum dose and duration of lutein/zeaxanthin intake that is associated with a clinically important change in macular pigment optical density (MPOD) or visual function.



Macular pigment, visual function, and macular disease among subjects with Alzheimer's disease: an exploratory study.

A clinical trial in AD patients designed to investigate the impact of macular carotenoid supplementation with respect to MP, visual function, and cognitive function is merited.

Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration.

It is demonstrated that lutein supplementation increases macular pigment optical density, as assessed with an objective study, and indicates that patients who show a pronounced increase in MPOD also benefit in terms of visual function.

Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration

The formulation containing all three macular carotenoids (Group 2 supplement) was the most efficacious in terms of achieving the highest combined concentration of the three MP constituent carotENoids in serum, thereby potentially optimising the bioavailability of these compounds for capture by the target tissue (retina).


Augmentation of the macular pigment optical density across its spatial profile and enhancements in contrast sensitivity were best achieved after supplementation with a formulation containing high doses of meso-zexanthin in combination with lutein and zeaxanthin.

Macular pigment optical density is related to cognitive function in older people.

BACKGROUND the xanthophylls lutein (L) and zeaxanthin (Z) exist in relatively high concentration in multiple central nervous tissues (e.g. cortex and neural retina). L + Z in macula (i.e. macular

The impact of macular pigment augmentation on visual performance using different carotenoid formulations.

Results suggest that supplementation with all three macular carotenoids potentially offered advantages over preparations lacking MZ, both in terms of MPOD response and visual performance enhancement.

Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study.

L supplementation increases MPOD levels in early stage AMD patients, and according to the VA measurements, the progress of the disease might be slowed in some patients with augmented levels of MP.